1. Home
  2. CTNM vs HWBK Comparison

CTNM vs HWBK Comparison

Compare CTNM & HWBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • HWBK
  • Stock Information
  • Founded
  • CTNM 2009
  • HWBK 1865
  • Country
  • CTNM United States
  • HWBK United States
  • Employees
  • CTNM N/A
  • HWBK N/A
  • Industry
  • CTNM
  • HWBK Major Banks
  • Sector
  • CTNM
  • HWBK Finance
  • Exchange
  • CTNM Nasdaq
  • HWBK Nasdaq
  • Market Cap
  • CTNM 174.6M
  • HWBK 199.0M
  • IPO Year
  • CTNM 2024
  • HWBK N/A
  • Fundamental
  • Price
  • CTNM $7.38
  • HWBK $30.03
  • Analyst Decision
  • CTNM Strong Buy
  • HWBK
  • Analyst Count
  • CTNM 4
  • HWBK 0
  • Target Price
  • CTNM $22.50
  • HWBK N/A
  • AVG Volume (30 Days)
  • CTNM 196.1K
  • HWBK 10.4K
  • Earning Date
  • CTNM 08-05-2025
  • HWBK 07-30-2025
  • Dividend Yield
  • CTNM N/A
  • HWBK 2.66%
  • EPS Growth
  • CTNM N/A
  • HWBK 396.63
  • EPS
  • CTNM N/A
  • HWBK 2.96
  • Revenue
  • CTNM N/A
  • HWBK $75,021,000.00
  • Revenue This Year
  • CTNM N/A
  • HWBK N/A
  • Revenue Next Year
  • CTNM N/A
  • HWBK N/A
  • P/E Ratio
  • CTNM N/A
  • HWBK $10.14
  • Revenue Growth
  • CTNM N/A
  • HWBK 33.44
  • 52 Week Low
  • CTNM $3.35
  • HWBK $21.35
  • 52 Week High
  • CTNM $20.55
  • HWBK $35.95
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • HWBK 59.31
  • Support Level
  • CTNM N/A
  • HWBK $29.88
  • Resistance Level
  • CTNM N/A
  • HWBK $30.87
  • Average True Range (ATR)
  • CTNM 0.00
  • HWBK 0.65
  • MACD
  • CTNM 0.00
  • HWBK 0.18
  • Stochastic Oscillator
  • CTNM 0.00
  • HWBK 69.68

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About HWBK Hawthorn Bancshares Inc.

Hawthorn Bancshares Inc is a financial holding company and along with its subsidiary, it conducts general banking and trust business, offering its customers checking and savings accounts, internet banking, certificates of deposit, trust services, brokerage services, and safety deposit boxes. The company also offers a range of lending services, including commercial and industrial loans, single payment personal loans, installment loans, and commercial and residential real estate loans.

Share on Social Networks: